Result: compared with wild-type mouse model, viral replication decreases about 10.06-fold in the rtL180M-rtM204V double mutants, but increases about 7.79-fold in the rtL180M-rtM204V-rtV173L triple mutants.
Result: suggesting that rtM204V and rtL180M double mutations in LAM-resistant HBV mutants resulted in the decline of replication ability, but the third compensatory rtV173L mutation significantly increased the HBV replication ab
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Abstract: Compared to the patients with the rtM204I mutant, patients with the rtM204V mutant had increased risk of virologic breakthrough (80% vs.
Abstract: In summary, lamivudine-resistant HBV patients with the rtM204V mutation have the highest risk of developing entecavir resistance, and entecavir monotherapy should be avoided.
Abstract: The presence of a HBV polymerase rtM204V mutation at the baseline was found to be the major risk factor for adverse outcomes.
Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Abstract: Among 6 sets of 20 clones obtained before salvage therapy, all clones harbored the rtM204V mutation, and ETV-resistant mutations were detected with the rtM204V in 108 clones.
Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
PMID: 23114756
2013
Antimicrobial agents and chemotherapy
Abstract: UDPS detected >=1 LAM resistance mutations (rtL80I/V, rtV173L, rtL180M, rtA181T, and rtM204I/V) in 10 (22%) of the 46 LAM-experienced subjects, including 5 in whom LAM resistance mutations were not identified by Sanger sequencing.
2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.
Abstract: FMCA demonstrated significant antiviral activity against wild-type as well as lamivudine-entecavir resistant triple mutant (L180M+M204V+S202G).
Abstract: Novel 2'-fluoro-6'-methylene-carbocyclic adenosine (FMCA) monophosphate prodrug (FMCAP) was synthesized and evaluated for its in vitro anti-HBV potency against a lamivudine-entecavir resistant clone (L180M+M204V+S202G).
A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus.
PMID: 23403838
2013
International journal of molecular medicine
Abstract: A novel resistance test method was developed by co-transfection with pHBV1.3-XhoI and -rtL180M/M204V and treatment with various NA concentrations.
Abstract: Different bands composed of pHBV1.3-XhoI or -rtL180M/M204V were used to distinguish NA susceptibility.
Abstract: The bands composed of pHBV1.3 were more sharply reduced by lamivudine (LMV) than -rtL180M/M204V.
High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Abstract: Both mutations, especially mutation rtM204V, were most often accompanied by compensatory mutations rtV173L and rtL180M but also by mutations conferring entecavir (n = 5) or adefovir resistance (n = 4).
Abstract: In this study mutational patterns of 60 HBV isolates harboring drug resistance mutations rtM204V or rtM204I were retrospectively analyzed.
Abstract: Interestingly, only one HBV clone carried the resistance mutations rtM204V and rtA181T.
Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected population.
Abstract: Notably, classical antiviral resistance mutations (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C /G/I -rtM204V/I-rtN236T-rtM250V) were n
Combination of allele-specific detection techniques to quantify minority resistance variants in hepatitis B infection: a novel approach.
PMID: 23454647
2013
Journal of virological methods
Result: Additional specificity testing was performed on single mutant templates (rtL180M, rtM204V, or rtV173L) and the double mutant template rtM204V and L180M, the most common clinically relevant double mutant.
Result: Previous consensus sequencing characterized the sample as containing HBV genotype A with the rtM204V mutation, but the additional rtV173L and rtL180M mutations were not detected (data not shown).
HBV mutation literature information.
PMID: 
2014
Acta pharmaceutica Sinica. B
Browser Board
Co-occurred Entities
Filtrator
ViMRT